HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (1) Citing Articles via Google Scholar Google Scholar Articles by Russell, N. Articles by Schmitz, N. Search for Related Content PubMed PubMed Citation Articles by Russell, N. Articles by Schmitz, N.

A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin’s lymphoma receiving chemotherapy

¹ Nottingham University Hospitals NHS Trust, Nottingham, UK
² Universitätsklinikum Münster, Münster, Germany
³ Saarland University Medical School, Homburg/Saar, Germany
⁴ University Hospital Gasthuisberg, Leuven, Belgium
⁵ Aalborg Hospital, Aarhus University, Aarhus, Denmark
⁶ Hospital Universitario de Salamanca, Salamanca, Spain
⁷ Amgen Ltd, Cambridge, UK
⁸ Amgen (Europe) GmbH, Zug, Switzerland and
⁹ Asklepios Klinik St. Georg, Hamburg, Germany

Correspondence: Professor Nigel Russell, Department of Hematology, Nottingham University Hospitals NHS Trust (City Campus), Nottingham NG5 1PB, United Kingdom. E-mail: nigel.russell{at}nottingham.ac.uk

Background: Growth factors are frequently used to aid peripheral blood progenitor cell mobilization from bone marrow. This phase 2 study examined the efficacy and safety of pegfilgrastim for mobilizing peripheral blood progenitors cells for autologous transplantation.

Design and Methods: Patients with non-Hodgkin’s lymphoma received one cycle of mobilizing chemotherapy (ifosfamide, carboplatin and etoposide, ICE). Twenty-four hours later they were randomized, double-blind, to receive a single dose of pegfilgrastim 6 mg or 12 mg, or filgrastim 5 µg/kg/day (until the end of leukapheresis). Following leukapheresis (collection phase), patients rested or received one or two ‘salvage’ cycles of ICE. High-dose BEAM chemotherapy was then given before peripheral blood progenitor cell transplantation. The primary end-point was the patients’ mean yield of CD34⁺ cells/kg during the collection phase.

Results: Ninety patients were randomized and received a study drug; 63% completed the collection phase. The patients’ mean (95% CI) CD34⁺ cell harvest per leukapheresis was 0.8 (0.5–1.4), 0.8 (0.5–1.6) and 1.2 (0.7–2.0)x10⁶ cells/kg for the pegfilgrastim 6 mg, pegfilgrastim 12 mg and filgrastim groups, respectively. Twenty (69%), 17 (59%) and 23 (72%) patients in these three groups achieved the targeted minimum harvest (2x10⁶ cells/kg). The mean total harvests were 1.7, 1.4 and 2.2x10⁶ cells/kg, respectively. Post-transplantation, the median days to absolute neutrophil count recovery (0.5x10⁹/L) were 12, 11, and 11, respectively. Pegfilgrastim and filgrastim were generally well tolerated.

Conclusions: Pegfilgrastim (6 or 12 mg) was effective for mobilizing peripheral blood progenitors cells in patients with non-Hodgkin’s lymphoma. These data may aid the design of studies to clarify optimal dosing and leukapheresis with pegfilgrastim.

Key words: filgrastim, pegfilgrastim, non-Hodgkin’s lymphoma, mobilization, peripheral blood progenitor cell transplantation.

This article has been cited by other articles:

				N. Skoetz, O. Weingart, I. Monsef, K. Bauer, C. Brillant, C. Herbst, S. Kluge, and A. Engert Ninth Biannual Report of the Cochrane Haematological Malignancies Group--Focus on Hematopoietic Growth Factors J Natl Cancer Inst, May 6, 2009; 101(9): E1 - E1. [Full Text]

				R. M. Lemoli and A. D'Addio Hematopoietic stem cell mobilization Haematologica, March 1, 2008; 93(3): 321 - 324. [Full Text] [PDF]